Rexahn Pharmaceuticals

Company Listings from SPi: Rexahn Pharmaceuticals

You are here: Home >> SPi Company Listings >> Rexahn Pharmaceuticals

 

Rexahn Pharmaceuticals

Website:
http://

Search for other references to "rexahn" on SPi News

Latest Rexahn Pharmaceuticals News

Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting ROCKVILLE, M.D., March 27, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies...... 12:00 GMT Wednesday 27th March 2019

Rexahn Pharmaceuticals Reports 2018 Financial Results ROCKVILLE, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies t...... 13:00 GMT Friday 8th March 2019

Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients ROCKVILLE, Md., March 04, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies t...... 13:00 GMT Monday 4th March 2019

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors ROCKVILLE, Md., March 01, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies t...... 13:00 GMT Friday 1st March 2019

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium ROCKVILLE, Md., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to...... 13:00 GMT Tuesday 19th February 2019

Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium ROCKVILLE, Md., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to...... 13:00 GMT Wednesday 6th February 2019

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types ROCKVILLE, Md., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to...... 13:00 GMT Monday 4th February 2019

Rexahn Announces Pricing of Public Offering of Common Stock and Warrants ROCKVILLE, Md., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced the pricing of an underwritten public offering of 10,750,000 s...... 14:00 GMT Wednesday 23rd January 2019

Rexahn Announces Proposed Public Offering of Common Stock and Warrants ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced that it intends to offer and sell shares of its common stock a...... 21:42 GMT Tuesday 22nd January 2019

Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to...... 12:30 GMT Tuesday 22nd January 2019

Buy Rexahn Pharmaceuticals
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us